Document Detail


ARISTOTLE RE-LYs on the ROCKET. What's new in stroke prevention in patients with atrial fibrillation?
MedLine Citation:
PMID:  22298161     Owner:  NLM     Status:  In-Data-Review    
Abstract/OtherAbstract:
Warfarin has long been considered the gold standard for stroke prevention in patients with atrial fibrillation (AF). Recently, three major trials comparing the efficacy and safety of new drugs: a thrombin inhibitor dabigatran and two inhibitors of factor Xa - rivaroxaban and apixaban, with that of warfarin, have been published. The aim of this paper is to present the main results of the RE-LY, ROCKET AF and ARISTOTLE trials, compare study populations and outcomes, and discuss clinical implications of their results for the long-term anticoagulation in patients with nonvalvular AF. (Cardiol J 2012; 19, 1: 4-10).
Authors:
Michał Tendera; Marcin Syzdół; Zofia Parma
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Cardiology journal     Volume:  19     ISSN:  1897-5593     ISO Abbreviation:  Cardiol J     Publication Date:  2012  
Date Detail:
Created Date:  2012-02-02     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101392712     Medline TA:  Cardiol J     Country:  Poland    
Other Details:
Languages:  eng     Pagination:  4-10     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Rational aspect ratio and suitable antibody coverage of gold nanorod for ultra-sensitive detection o...
Next Document:  Predictors of local venous complications resulting from electrophysiological procedures.